As part of San Francisco Litquake festival, Sonia Arrison, author of 100 Plus, David Ewing Duncan, writer of When I'm 164, join the great futurist Paul Saffo to discuss what happens to humans if the science of anti-aging succeeds.
Sonia Arrison is a technology analyst and bestselling author of 100 Plus: How the Coming Age of Longevity Will Change Everything, From Careers and Relationships to Family and Faith. She is a founder and trustee of Singularity University.
David Ewing Duncan
David Ewing Duncan is an award-winning, best-selling author of eight books published in 21 languages. He is a founder and co-curator of Arc Programs. David is a columnist for Newsweek, a correspondent for The Atlantic and the chief correspondent for NPR Talk’s Biotech Nation. David writes for The New York Times, Fortune, Wired, National Geographic, Discover and many other publications. He is a former commentator for NPR’s Morning Edition and a special correspondent and producer for ABC’s Nightline and 20/20, and correspondent for NOVA’s ScienceNow!. His latest book is When I’m 164: The new science of radical life extension, and what happens if it succeeds. He also wrote Experimental Man: What One Man’s Body Reveals about His Future, Your Health, and Our Toxic World (Wiley). He was the founder and director of the BioAgenda Institute, and the founding director of the Center of Life Science Policy at UC Berkeley. David is finishing his first novel, a biomedical thriller. David’s work has won numerous awards, including Magazine Story of the Year from the American Association for the Advancement of Science. His articles have twice been cited in nominations for National Magazine Awards, and his work has appeared twice in The Best American Science and Nature Writing. David lives in San Francisco and is a member of the SF Writer’s Grotto. His website is www.davidewingduncan.com.
Paul Saffo is a forecaster with over two decades experience exploring the dynamics of large-scale, long-term change. He is Managing Director of Foresight at Discern Analytics, teaches at Stanford University and is a researcher through mediaX at Stanford University. Saffo serves on a variety of not-for-profit boards including the Long Now Foundation, and the Bay Area Council Economic Institute. Saffo’s essays have appeared in a wide range of publications including The Harvard Business Review, Fortune, Wired, The Los Angeles Times, Newsweek, The New York Times, and the Washington Post. Saffo holds degrees from Harvard College, Cambridge University and Stanford University.
David Ewing Duncan, author of When I'm 164, questions the benefits of living to an advanced age. Despite medical advancement that promise greater expectancy and wellness, Duncan shares that many seniors do not wish to live to extreme ages.
Technology forecaster Paul Saffo ponders whether advancements in science and medicine would compel society to lengthen the lives of the world's greatest geniuses. Saffo also discusses the influence of people who bloomed later in life.